Analysis Of Income And Expense [Abstract]

Xbrane Biopharma - Filing #689992

Concept 2022-01-01 to
2022-12-31
2022-01-01 to
2022-12-31
2022-01-01 to
2022-12-31
2022-01-01 to
2022-12-31
2022-01-01 to
2022-12-31
2021-01-01 to
2021-12-31
2021-01-01 to
2021-12-31
2021-01-01 to
2021-12-31
2021-01-01 to
2021-12-31
2021-01-01 to
2021-12-31
Analysis of income and expense [abstract]
Revenue [abstract]
Revenue
57 618 SEK
10 709 SEK
Material income and expense [abstract]
Research and development expense
199 648 SEK
160 619 SEK
Finance income (cost)
2 296 SEK
2 643 SEK
Comprehensive income, continuing and discontinued operations [abstract]
Comprehensive income
SEK
167 356 SEK
SEK
172 513 SEK
5 157 SEK
SEK
SEK
1 220 SEK
187 156 SEK
188 376 SEK
Comprehensive income attributable to owners of parent, continuing and discontinued operations [abstract]
Comprehensive income, attributable to owners of parent
167 356 SEK
187 156 SEK
Comprehensive income attributable to non-controlling interests, continuing and discontinued operations [abstract]
Comprehensive income, attributable to non-controlling interests
SEK
SEK

Talk to a Data Expert

Have a question? We'll get back to you promptly.